{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:51:05Z","timestamp":1792183865762,"version":"4.4.0"},"reference-count":86,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly prescribed for the management of type 2 diabetes mellitus (T2DM). However, the potential connection between GLP-1 RAs and the risk of pancreatitis presents a complex and nuanced issue. Although these drugs are effective in improving blood sugar control and cardiovascular health, their association with pancreatitis remains an area of concern. Our study aims to evaluate the association between the use of GLP-1 RAs, considered as a single class, and the risk of pancreatitis in a comorbidity-free subgroup of patients with type 2 diabetes mellitus (T2DM) in the United States. Methods: Data were retrieved from the TriNetX research database using the US Collaborative Network, which included information from 61 healthcare organizations within the U.S. Patients diagnosed with T2DM were categorized into two cohorts: one consisting of the patients prescribed with GLP-1 RAs and the other comprising patients who did not receive GLP-1 RAs. Of this class of medications, the agents analyzed were dulaglutide, lixisenatide, exenatide, liraglutide, and semaglutide. Using a 1:1 propensity score matching (PSM) model, we matched patients of both cohorts based on baseline demographics, comorbidities (hypertensive disorders, ischemic heart disease, gallstones, annular pancreas, alcohol use disorders, hypertriglyceridemia, hypercalcemia, cystic fibrosis, and cannabis use), medications known to cause drug-related pancreatitis, and laboratory values. Results: Of 969,240 patients with T2DM, 9.7% (93,608) were on GLP-1 RA, and 90.3% (875,632) were not. After PSM, the sample included 81,872 patients in each cohort. The risk of pancreatitis between the two groups was not statistically different between the two cohorts at 6 months at (0.1% vs. 0.1%, p = 0.04), and remained without significant increase with time; at 1 year (0.1% vs. 0.2%, p = 0.02), 3 years (0.2% vs. 0.3%, p = 0.001), and 5 years (0.3% vs. 0.4%, p &lt; 0.001). The lifetime risk of developing pancreatitis in patients on GLP-1 RA was lower (0.3% vs. 0.4%, p &lt; 0.001). Conclusions: In our comorbidity-free U.S.-based population with T2DM, the use of GLP-1 RAs did not increase their risk of pancreatitis. Their use was associated with a lower lifetime risk of pancreatitis.<\/jats:p>","DOI":"10.3390\/jcm14030944","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:13:43Z","timestamp":1738646023000},"page":"944","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6518-3971","authenticated-orcid":false,"given":"Mark","family":"Ayoub","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Charleston Area Medical Center, West Virginia University, Charleston, WV 25304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-1857","authenticated-orcid":false,"given":"Harleen","family":"Chela","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Charleston Area Medical Center, West Virginia University, Charleston, WV 25304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisar","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Charleston Area Medical Center, West Virginia University, Charleston, WV 25304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Hunter","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Charleston Area Medical Center, West Virginia University, Charleston, WV 25304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javaria","family":"Anwar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Charleston Area Medical Center, West Virginia University, Charleston, WV 25304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6796-9359","authenticated-orcid":false,"given":"Veysel","family":"Tahan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Charleston Area Medical Center, West Virginia University, Charleston, WV 25304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-1704","authenticated-orcid":false,"given":"Ebubekir","family":"Daglilar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Charleston Area Medical Center, West Virginia University, Charleston, WV 25304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jcpt.13230","article-title":"A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents","volume":"45","author":"Cornell","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2337\/cd22-0027","article-title":"Glucagon-like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes\u2014So Why Is Their Uptake So Low?","volume":"41","author":"King","year":"2023","journal-title":"Clin. Diabetes"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1464-5491.2012.03652.x","article-title":"Research: Treatment: Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: A follow-up study","volume":"29","author":"Wenten","year":"2012","journal-title":"Diabet. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1463-1326.2011.01376.x","article-title":"A cohort study of acute pancreatitis in relation to exenatide use","volume":"13","author":"Dore","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"ref_9","unstructured":"(2025, January 09). National Diabetes Statistics Report|Diabetes|CDC, Available online: https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e076261","DOI":"10.1136\/bmjopen-2023-076261","article-title":"Prevalence of comorbidities and its associated factors among type-2 diabetes patients: A hospital-based study in Jashore District, Bangladesh","volume":"13","author":"Shuvo","year":"2023","journal-title":"BMJ Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s11136-004-6640-4","article-title":"Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey","volume":"14","author":"Maddigan","year":"2005","journal-title":"Qual. Life Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed, N.A., Aleppo, G., Bannuru, R.R., Bruemmer, D., Collins, B.S., Ekhlaspour, L., Gaglia, J.L., Hilliard, M.E., and Johnson, E.L. (2024). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142024. Diabetes Care, 47, S158\u2013S178.","DOI":"10.2337\/dc24-S009"},{"key":"ref_13","unstructured":"Collins, L., and Costello, R.A. (2023). Glucagon-like Peptide-1 Receptor Agonists, StatPearls."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13300-010-0013-5","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications","volume":"2","author":"Unger","year":"2011","journal-title":"Diabetes Therapy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00572873","article-title":"Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation","volume":"30","author":"Nauck","year":"1993","journal-title":"Acta Diabetol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajem.2024.01.010","article-title":"GLP-1 RAs: A review for emergency clinicians","volume":"78","author":"Long","year":"2024","journal-title":"Am. J. Emerg. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., and Zhang, Y. (2021). GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.721135"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 RAs: A systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1038\/s41467-024-50199-y","article-title":"GLP-1 receptor agonists\u2019 impact on cardio-renal outcomes and mortality in T2D with acute kidney disease","volume":"15","author":"Pan","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.23876\/j.krcp.22.001","article-title":"GLP-1 receptor agonists in diabetic kidney disease: Current evidence and future directions","volume":"41","author":"Yu","year":"2022","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 Receptor Agonists and the Risk of Thyroid Cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","article-title":"GLP-1: Molecular mechanisms and outcomes of a complex signaling system","volume":"128","author":"Smith","year":"2019","journal-title":"Neurochem. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1210\/mend-5-1-111","article-title":"Cloning and primary sequence of a mouse candidate prohormone convertase PC1 homologous to PC2, Furin, and Kex2: Distinct chromosomal localization and messenger RNA distribution in brain and pituitary compared to PC2","volume":"5","author":"Seidah","year":"1991","journal-title":"Mol. Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.physbeh.2017.02.039","article-title":"Signalling in the gut endocrine axis","volume":"176","author":"Gribble","year":"2017","journal-title":"Physiol. Behav."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nm1168","article-title":"Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120","volume":"11","author":"Hirasawa","year":"2005","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3945\/ajcn.112.047563","article-title":"Contribution of gastroenteropancreatic appetite hormones to protein-induced satiety","volume":"97","author":"Belza","year":"2013","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000201231","article-title":"Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients","volume":"56","author":"Herrmann","year":"1995","journal-title":"Digestion"},{"key":"ref_33","first-page":"R582","article-title":"Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus","volume":"277","author":"Rinaman","year":"1999","journal-title":"Am. J. Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"R470","DOI":"10.1152\/ajpregu.00732.2002","article-title":"Gastric distension induces c-Fos in medullary GLP-1\/2-containing neurons","volume":"285","author":"Vrang","year":"2003","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2337\/db11-0489","article-title":"CCK stimulation of GLP-1 neurons involves \u03b11-adrenoceptor-mediated increase in glutamatergic synaptic inputs","volume":"60","author":"Hisadome","year":"2011","journal-title":"Diabetes"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1210\/en.2009-0220","article-title":"Minireview: Finding the Sweet Spot: Peripheral Versus Central Glucagon-Like Peptide 1 Action in Feeding and Glucose Homeostasis","volume":"150","author":"Williams","year":"2009","journal-title":"Endocrinology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1566-0702(02)00182-0","article-title":"Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons","volume":"102","author":"Kakei","year":"2002","journal-title":"Auton. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1365-2982.2009.01317.x","article-title":"Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat","volume":"21","author":"Bucinskaite","year":"2009","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0167-0115(98)00044-5","article-title":"Amidated and non-amidated glucagon-like peptide-1 (GLP-1): Non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans","volume":"77","author":"Wettergren","year":"1998","journal-title":"Regul. Pept."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2337\/diab.42.5.658","article-title":"Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable","volume":"42","author":"Wettergren","year":"1993","journal-title":"Diabetes"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diab.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans","volume":"43","author":"Wettergren","year":"1994","journal-title":"Diabetes"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmet.2016.10.007","article-title":"Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis","volume":"25","author":"Mulvihill","year":"2017","journal-title":"Cell Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspecturn Venom Further Evidence for an Exendin Receptor on Dispersed Acini from Guinea Pig Pancreas*","volume":"267","author":"Engsbli","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/TCRM.S7313","article-title":"Selecting GLP-1 RAs in the management of type 2 diabetes: Differential pharmacology and therapeutic benefits of liraglutide and exenatide","volume":"6","author":"Pinkney","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_45","unstructured":"(2024, May 05). GLP1 Receptor Agonists in Type 2 Diabetes Anunderused Asset Updated January 2021-PCDS. Available online: https:\/\/www.pcdsociety.org\/resources\/details\/glp-1-receptor-agonists-type-2-diabetes-underused-asset-updated-january-2021."},{"key":"ref_46","unstructured":"Latif, W., Lambrinos, K.J., and Rodriguez, R. (2023). Compare and Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs), StatPearls."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/ijcp.12847","article-title":"Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: A systemic review of randomised controlled trials","volume":"70","author":"Xue","year":"2016","journal-title":"Int. J. Clin. Pract."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","article-title":"An overview of GLP-1 RAs and recent cardiovascular outcomes trials","volume":"96","author":"Sheahan","year":"2020","journal-title":"Postgrad. Med. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01106-4","article-title":"Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: Combined post hoc analysis of the SUSTAIN and PIONEER trials","volume":"19","author":"Husain","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2042018821997320","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: An updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_58","first-page":"101","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1573399812666151223093841","article-title":"Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy","volume":"12","author":"Drab","year":"2016","journal-title":"Curr. Diabetes Rev."},{"key":"ref_60","unstructured":"(2024, May 05). FDA Drug Safety Communication: FDA Investigating Reports of Possible Increased Risk of Pancreatitis and Pre-Cancerous Findings of the Pancreas from Incretin Mimetic Drugs for Type 2 Diabetes|FDA, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre."},{"key":"ref_61","unstructured":"(2024, April 19). FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes|FDA, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-glp-1-treatment-type-2-diabetes."},{"key":"ref_62","unstructured":"(2024, April 19). FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight|FDA, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ayoub, M., Faris, C., Juranovic, T., Chela, H., and Daglilar, E. (2024). The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study. Cancers, 16.","DOI":"10.3390\/cancers16091625"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e2350408","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw. Open."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"206","DOI":"10.23736\/S2724-6507.20.03219-8","article-title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials","volume":"48","author":"Nreu","year":"2023","journal-title":"Minerva Endocrinol."},{"key":"ref_66","unstructured":"(2024, February 20). Trulicity (Dulaglutide) Prescribing Information Indianapolis, Indiana: Eli Lilly and Company. Available online: https:\/\/pi.lilly.com\/us\/trulicity-uspi.pdf."},{"key":"ref_67","first-page":"357","article-title":"Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 RA","volume":"41","author":"Smith","year":"2016","journal-title":"Pharm. Ther."},{"key":"ref_68","unstructured":"(2024, February 20). Adlyxin (Lixisenatide) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208471orig1s000lbl.pdf."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/8755122517711958","article-title":"Lixisenatide: A New Option for Managing Type 2 Diabetes","volume":"33","author":"Newsome","year":"2017","journal-title":"J. Pharm. Technol."},{"key":"ref_70","unstructured":"(2024, February 20). Package Insert. Bydureon (Exenatide), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021773s9s11s18s22s25lbl.pdf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4158\/EP09104.CRR","article-title":"Exenatide-induced acute pancreatitis","volume":"16","author":"Ayoub","year":"2010","journal-title":"Endocr. Pract."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/diacare.29.02.06.dc05-2043","article-title":"Exenatide (exendin-4)-induced pancreatitis: A case report","volume":"29","author":"Denker","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1089\/dia.2012.0075","article-title":"Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population","volume":"14","author":"Romley","year":"2012","journal-title":"Diabetes Technol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7570\/jomes20059","article-title":"Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes","volume":"30","author":"Seo","year":"2021","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4158\/EP11290.OR","article-title":"Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting","volume":"18","author":"Lando","year":"2012","journal-title":"Endocr. Pract."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Tilinca, M.C., Tiuca, R.A., Burlacu, A., and Varga, A. (2021). A 2021 update on the use of liraglutide in the modern treatment of \u2018diabesity\u2019: A narrative review. Medicina, 57.","DOI":"10.3390\/medicina57070669"},{"key":"ref_77","unstructured":"(2024, February 20). Victoza (Liraglutide) Package Insert, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022341s027lbl.pdf."},{"key":"ref_78","unstructured":"(2024, February 20). Ozempic (Semaglutide) Package Insert, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e1289","DOI":"10.14309\/01.ajg.0000864036.15004.08","article-title":"S1849ch out for Semaglutide: Potential Cause of Pancreatitis?","volume":"117","author":"Patel","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_80","first-page":"e43773","article-title":"Acute Pancreatitis in a Patient Taking Semaglutide","volume":"15","author":"Patel","year":"2023","journal-title":"Cureus"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Smits, M.M., and Van Raalte, D.H. (2021). Safety of Semaglutide. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.645563"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1185\/03007990902820519","article-title":"Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide","volume":"25","author":"Dore","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Ayoub, M., Aibani, R., Dodd, T., Ceesay, M., Bhinder, M., Faris, C., Amin, N., and Daglilar, E. (2024). Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis. Cancers, 16.","DOI":"10.3390\/cancers16183224"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"g2366","DOI":"10.1136\/bmj.g2366","article-title":"Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: Systematic review and meta-analysis of randomised and non-randomised studies","volume":"348","author":"Li","year":"2014","journal-title":"BMJ"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic Safety of Incretin-Based Drugs\u2014FDA and EMA Assessment","volume":"370","author":"Egan","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s00125-014-3231-y","article-title":"Risk of pancreatitis in patients treated with incretin-based therapies","volume":"57","author":"Meier","year":"2014","journal-title":"Diabetologia"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/944\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:25:32Z","timestamp":1760027132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":86,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14030944"],"URL":"https:\/\/doi.org\/10.3390\/jcm14030944","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}